Get 40% Off
🚀 AI-picked stocks soar in May. PRFT is +55%—in just 16 days! Don’t miss June’s top picks.Unlock full list

ImmunoCellular suspends patient randomization in late-stage study of ICT-107 due to lack of money

Published 06/21/2017, 07:13 AM
© Reuters.  ImmunoCellular suspends patient randomization in late-stage study of ICT-107 due to lack of money
IMUC
-
  • Thinly traded nano cap ImmunoCellular Therapeutics (NYSEMKT:IMUC) is poised for a down day today after it announced that it has suspended patient randomization in its Phase 3 clinical trial assessing lead product candidate ICT-107 for the treatment of newly diagnosed glioblastoma due to insufficient financial resources.
  • The company says that it will continue evaluate/explore strategic alternatives including a merger, reorganization or other business combination.
  • Previously: ImmunoCellular down 20% on money woes (May 16)
  • Now read: Stryker Strikes Again, But Quality Does Not Come Cheap


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.